Evolving trends in induction therapy

Transplantation Reviews

Volumn 23, Issue 2, 2009, Pages 94-102

  Arias, Marta ^a   Campistol, Josep M ^a   Vincenti, Flavio ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ARTICLE; CHILL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG EDEMA; MALIGNANT NEOPLASTIC DISEASE; MENINGOENCEPHALITIS; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; SIDE EFFECT; THERAPY RESISTANCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 61949152691     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2009.01.004     Document Type: Article

References (79)

1. Starzl T.E., Marchioro T.L., Porter K.A., Iwasaki Y., and Cerilli G.J. The use of heterologous antilymphoid agents in canine renal and liver homotransplantations and in human renal homotransplantations. Surg Gynecol Obstet 124 (1967) 301-308
2. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., and Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378-383
3. Cecka J.M., and Terasaki P.I. The UNOS scientific renal transplant registry. United Network for Organ Sharing. Clin Transpl (1995) 1-18
4. Tullius S.G., and Tilney N.L. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 59 (1995) 313-318
5. Vella J.P., and Sayegh M.H. Current and future immunosuppressive therapies: impact on chronic allograft dysfunction. J Nephrol 10 (1997) 229-231
6. Vella J.P., and Sayegh M.H. Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J 73 (1997) 386-390
7. Denton M.D., Magee C.C., and Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 353 (1999) 1083-1091
8. Gummert J.F., Ikonen T., and Morris R.E. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10 (1999) 1366-1380
9. Kanmaz T., and Knechtle S.J. Novel agents or strategies for immunosuppression after renal transplantation. Curr Opin Organ Transplant 8 (2003) 172-178
10. Kahan B.D. Individuality: the barrier to optimal immunosuppression. Nat Rev Immunol 3 (2003) 831-838
11. Tedesco H., Pinheiro P., Rosso C., and Medina J.O. Immunotherapy for de novo renal transplantation: what's in the pipeline?. Drugs 66 (2006) 1665-1684
12. Brent L. A history of transplantation immunology (1997), Academic Press, New York
13. Metchnikoff E. Étude sur la resorption des cellules. Ann Inst Pasteur 13 (1899) 737-769
14. Woodruff M.F.A., and Forman B. Effects of antilymphocyte serum on suspension of lymphocytes in vitro. Nature 168 (1951) 35-36
15. Gibson T., and Medawar P.B. The fate of skin homografts in man. J Anat 77 (1943) 299-310
16. Medawar P.B. The behaviour and fate of skin autografts and skin homografts in rabbits. J Anat 78 (1944) 176-199
17. Monaco AP: Antiserum to lymphocytes: prolonged survival of canine renal allografts. Science 153 (1961) 1264-1267
18. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
19. Szczech L.A., Berlin J.A., Aradhye S., Grossman R.A., and Feldman H.I. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 8 (1997) 1771-1777
20. Bell L., Girardin C., Sharma A., Goodyer P., and Mazer B. Lymphocyte subsets during and after rabbit anti-thymocyte globulin induction in pediatric renal transplantation: sustained T cell depletion. Transplant Proc 29 (1997) 6S-9S
21. Storb R. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 44 (1974) 56-75
22. Murdock R. Thymoglobulin (2002), SangStat Medical Corporation, Fremont (Calif) [package insert]
23. Somerville K.T. Antibody agents in solid organ transplantation. J Pharm Pract 16 (2003) 388-400
24. Crosnier J., Kreis H., Descamps J.M., and Mansouri R. Are there non-steroid-dependent rejection episodes?. Proc Eur Dial Transpl Assoc 17 (1980) 391-395
25. Schroeder T.J., First M.R., Mansour M.E., Alexander J.W., and Penn I. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kidney Dis 14 5 Suppl 2 (1989) 14-18
26. Pomer S., Waldherr R., Mohring K., Kempter F., Wiesel M., and Weimer R. Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results. Transplant Proc 24 (1992) 1732-1733
27. Abramowicz D., Goldman M., De Pauw L., Vanherweghem J.L., Kinnaert P., and Vereerstraeten P. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-centre, prospective, randomized study. Transplantation 54 (1992) 433-437
28. Lange H. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transpl Int 12 (1999) 2-9
29. Brennan D.C. A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67 (1999) 1011-1018
30. Opelz G., and Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342 (1993) 1514-1516
31. Cockfield S.M., Preiksaitis J.K., Jewell L.D., and Parfrey N.A. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single centre. Transplantation 56 (1993) 88-96
32. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313 (1985) 337-342
33. Kuypers D.R., and Vanrenterghem Y.F. Monoclonal antibodies in renal transplantation: old and new. Nephrol Dial Transplant 19 (2004) 297-300
34. Woodle E.S., Thistlethwaite J.R., Jolliffe L.K., et al. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol 148 (1992) 2756
35. Norman D.J., Vincenti F., de Mattos A.M., et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 70 (2000) 1707-1712
36. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338 (1998) 161-165
37. Kahan B.D., Rajagopalan P.R., Hall M., and for the United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 67 (1999) 276-284
38. Nashan B., Moore R., Amlot P., Schmidt A.G., Abeywickrama K., Soulillou J.P., and for the CHIB 201 International Study Group. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350 (1997) 1193-1198
39. Soulillou J.P., Cantarovich D., Le Mauff B., et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322 (1990) 1175-1182
40. Sollinger H., Kaplan B., Pescovitz M.D., et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 72 (2001) 1915-1919
41. Brennan D.C., Daller J.A., Lake K.D., Cibrik D., Del Castillo D., and Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355 (2006) 1967-1977
42. Mourad G., Rostaing L., Legendre C., Garrigue V., Thervet E., and Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584-590
43. Nashan B., Light S., Hardie I.R., Lin A., Johnson J.R., and for the Daclizumab Double Therapy Study Group. Transplantation 67 (1999) 110-115
44. Ciancio G., Burke G.W., Suzart K., et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 73 (2002) 1100-1106
45. Webster A.C., Playford E.G., Higgins G., Chapman J.R., and Craig J.C. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77 (2004) 166-176
46. Vincenti F., Pace D., Birmbaum J., and Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 3 (2003) 50-52
47. Light J.A., Sasaki T.M., Ghasemian R., Barhyte D.Y., and Fowlkes D.L. Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation. Clin Transplant 16 Suppl 7 (2002) 30-33
48. Kuypers D.R.J., Evenepoel P., Maes B., Coosemans W., Pirenne J., and Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 17 (2003) 234-241
49. Vincenti F., Ramos E., Bratstrom C., et al. Multicentre trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71 (2001) 1282-1287
50. Flechner S.M., Goldfarb D., Modlin C., et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomised trial of sirolimus versus cyclosporine. Transplantation 74 (2002) 1070-1076
51. Ekberg H. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 7 (2007) 560-570
52. Frei U., Daloze P., Vitko S., et al. Characterization of acute rejections and associated relative risk factors in the Symphony Study. Abstract 245, American Transplant Congress (ATC) (2007)
53. Calne R., Moffatt S.D., and Friend P.J. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68 (1999) 1613-1616
54. Kirk A.D., Hale D.A., Mannon R.B., and Kleiner D.E. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath 1H). Transplantation 76 (2003) 120-129
55. Tan H.P., Kaczorowski D.J., and Basu A. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation 78 (2004) 1683-1688
56. Watson C.J., Bradley J.A., and Friend P.J. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 5 (2005) 1347-1353
57. Vathsala A., Ona E.T., and Tan S.Y. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80 (2005) 765-774
58. Ciancio G., Burke G.W., and Gaynor J.J. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 80 (2005) 457-465
59. Thomas P.G., Woodside K.J., Lappin J.A., Vaidya S., Rajaraman S., and Gugliuzza K.K. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 83 (2007) 1509-1512
60. Morris P.J., and Russell N.K. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81 (2006) 1361-1367
61. Knechtle S.J., Fernandez L.A., and Pirsch J.D. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 136 (2004) 754-760
62. Shapiro R., Basu A., and Tan H. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J Am Coll Surg 200 (2005) 505-515
63. Kaufman D.B., Leventhal J.R., and Axelrod D. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant 5 (2005) 2539-2548
64. Ciancio G., Burke G.W., and Gaynor J.J. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 78 (2004) 426-433
65. Tan H.P., Kaczorowski D.J., and Basu A. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 6 (2006) 2409-2417
66. Vincenti F. Chronic induction. What's new in the pipeline?. Contrib Nephrol 146 (2005) 22-29
67. Salomon B., and Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19 (2001) 225-252
68. Elster E.A., Xu H., Tadaki D.K., et al. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation 72 (2001) 1473-1478
69. Cho C.S., Burkly L.C., Fechner Jr. J.H., et al. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody co-stimulatory molecule blockade in rhesus renal allograft recipients. Transplantation 72 (2001) 587-597
70. Moreland L.W., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46 (2002) 1470-1479
71. Levisetti M.G., Padrid P.A., Szot G.L., et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 159 (1997) 5187-5191
72. Larsen C.P., Pearson T.C., Adams A.B., et al. Rationale development of LEA29Y (Belatacept), a high affinity variant of CTLA4Ig with potent immunosuppressive properties. Am J Transplant 5 (2005) 443-453
73. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with Belatacept in renal transplantation. N Engl J Med 353 (2005) 770-781
74. Yabu J.M., and Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol 27 (2007) 479-486
75. Powell J.D., Lerner C.G., and Schwartz R.H. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 162 (1999) 2775-2784
76. Arnaout M.A. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75 (1990) 1037-1050
77. Vincenti F., Mendez R., Pescovitz M., et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 7 (2007) 1770-1777
78. Silva A.J., Da Brickelmaier M., Majeau G.R., Li Z., Su L., and Hsu Y.M. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 168 (2002) 4462-4471
79. Toor A.A., Stiff P.J., Nickoloff B.J., Rodriguez T., Klein J.L., and Gordon K.B. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat 18 (2007) 13-18